- Now that Valeant has secured sufficient funding, it is better positioned to make a bid for gastroenterology-focused Salix Pharmaceuticals.
- According to Bloomberg reports, if Valeant bids, the per-share price will be more than $150.
- When the news broke, Salix's stock was up to almost $150 per share.
After a period of relative quiet, following the scuttled acquisition bid for Allergan, and careful reconsideration of their approach to M&A, Valeant may be ready to hit the acquisition trail again with a bid for NC-based Salix Pharmaceuticals. With a total price of less than $10 billion, this acquisition is far less pricey than Allergan would have been, but would still represent a valuable addition to Valeant's portfolio.